Ingersoll Rand Earnings Call Signals Steady, Cautious Growth
Ingersoll Rand Inc. ((IR)) has held its Q4 earnings call. Read on for the main highlights of the call.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ingersoll Rand’s latest earnings call struck a notably upbeat tone despite visible macro headwinds and tariff pressure. Management emphasized strong adjusted EBITDA, disciplined capital deployment, and accelerating recurring revenue, while openly flagging a modest organic revenue dip for 2025 and cautious 2026 assumptions that deliberately exclude any cyclical rebound.
Orders and Revenue Show Solid Q4 Momentum
Q4 orders rose 8% year over year, with organic growth of 1%, suggesting demand is holding up even as some customers delay decisions. Revenue climbed 10% in the quarter, with 3% organic growth, giving the company tangible momentum as it heads toward 2026.
EBITDA and Margins Beat Prior Expectations
Adjusted EBITDA reached $580 million in Q4, with a robust margin of 27.7%, reflecting strong execution and cost control. For the full year, adjusted EBITDA was about $2.1 billion at a 27.4% margin, topping the upper end of management’s previous guidance range.
EPS Growth Remains Resilient
Adjusted earnings per share came in at $0.96 for Q4, up 14% from a year earlier, underscoring solid profitability despite margin headwinds. Full‑year adjusted EPS was $3.34, up 2%, and the 2026 outlook of $3.45–$3.57 points to roughly 5% growth at the midpoint.
Recurring Revenue Becomes a Growth Engine
Recurring revenue surpassed $450 million in 2025, building a more predictable earnings base for investors. The company now holds a roughly $1.1 billion backlog of future contracted recurring revenue, a sharp increase from around $200 million just a few years ago.
M&A Execution and Pipeline Underpin Future Growth
Ingersoll Rand invested $525 million across 16 deals in 2025, adding about $275 million of annualized inorganic revenue at an average presynergy multiple of roughly 9 times. Management also highlighted nine deals under letter of intent and the closing of Synomics in January 2026, pointing to a deep and active pipeline.
Capital Deployment and Balance Sheet Stay Powerful
The company repurchased $1.0 billion of its own shares and paid $32 million in dividends during 2025, reinforcing its shareholder‑friendly stance. With $3.8 billion of liquidity, leverage well below 2 times, and Q4 cash flow of $462 million, management has ample flexibility to fund deals and buybacks.
PST Life Sciences Drives Segment-Level Outperformance
Within PST, Q4 orders rose 6% year over year, including 1% organic growth, with life sciences organic orders growing in the mid‑teens. PST revenue rose 8% in the quarter, 4% organically, while adjusted EBITDA jumped 19% to $127 million and margin expanded 280 basis points to 30.4%.
Asia, Including China, Delivers Notable Wins
ITS Q4 orders were up 9%, with organic gains in the low single digits, supported by strong performance in Asia Pacific. APAC grew in the low double digits overall, China delivered low single‑digit growth, and the rest of Asia rose in the mid‑twenties, fueled by localized products and new technology integrations.
Full-Year Organic Revenue Slightly Contracts
Total revenue increased 6% for the year, but organic revenue dipped 1%, largely due to tough comparisons in the first half. The modest organic decline shows the limits of the current demand environment even as acquisitions and pricing help lift reported growth.
Tariffs and Reinvestment Weigh on Margins
Management pointed to tariffs and strategic commercial reinvestments as the main sources of year‑on‑year margin pressure. In the ITS segment, Q4 adjusted EBITDA margin slipped to 28.9%, reflecting tariff dilution and spending aimed at capturing future growth.
Book-to-Bill Slips Below One on Seasonality
The overall Q4 book‑to‑bill ratio came in at 0.93, with both segments falling under one, including 0.96 for PST, reflecting normal year‑end seasonality. Some shipment timing also contributed, signaling that orders temporarily lagged revenue rather than a structural demand drop.
Cautious Organic Assumptions for 2026
The 2026 framework embeds just 1% organic order growth at the midpoint, a conservative stance that assumes no meaningful market inflection. Management stressed that the guide reflects today’s trajectory rather than any anticipated macro recovery, leaving upside if conditions improve.
Long-Cycle Project Decisions Remain Slow
Executives noted customers are taking longer to green‑light long‑cycle projects, which delays converting a healthy pipeline into revenue. These are described as timing delays rather than cancellations, suggesting the demand is intact but slower to materialize.
EMEA Weakness Highlights Regional Unevenness
ITS organic orders in EMEA fell in the mid single digits in Q4, a setback mainly attributed to project timing issues. Management emphasized that full‑year results in the region remained positive, but the quarter underscores a patchy macro backdrop.
Tariffs Also Pressure Working Capital and FCF
Tariff dynamics have forced the company to build inventory, putting pressure on working capital and dampening free‑cash‑flow conversion. Improving inventory turns and working capital discipline is now a clear focus area to unlock stronger cash generation.
Guidance Signals Modest Growth with Upside Optionality
For 2026, Ingersoll Rand expects revenue to grow 2.5%–4.5%, driven by about 1% organic growth, roughly 1.5% from M&A and about a 1% currency tailwind. Adjusted EBITDA is projected at $2.13–$2.19 billion, EPS at $3.45–$3.57, and free cash‑flow conversion around 95%, all based on no assumed market recovery and low single‑digit organic gains from Q2 onward.
In sum, the earnings call painted a picture of a company executing well, leaning on recurring revenue, M&A, and disciplined capital allocation to offset near‑term macro and tariff headwinds. With conservative guidance, a strong balance sheet, and clear levers for growth, Ingersoll Rand appears positioned for steady if unspectacular gains, with potential upside if industrial demand accelerates.
